ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $60,860.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Krista Davis also recently made the following trade(s):

• On Friday, February 21st, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00.
• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $63.26 on Thursday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm’s fifty day moving average price is $57.98 and its two-hundred day moving average price is $58.07. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The firm has a market capitalization of $1.38 billion, a P/E ratio of -115.02 and a beta of 0.62.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ANIP. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a report on Wednesday. They set an “overweight” rating and a $85.00 target price for the company. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares in the last quarter. Exchange Traded Concepts LLC raised its position in ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after acquiring an additional 310 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock worth $582,000 after acquiring an additional 364 shares in the last quarter. New York State Teachers Retirement System raised its position in ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after acquiring an additional 394 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after purchasing an additional 412 shares during the period. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.